These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 36061356)

  • 1. The Efficacy of Immune Checkpoint Inhibitors vs. Chemotherapy for KRAS-Mutant or EGFR-Mutant Non-Small-Cell Lung Cancers: A Meta-Analysis Based on Randomized Controlled Trials.
    Chen W; Li L; Cheng S; Yu J
    Dis Markers; 2022; 2022():2631852. PubMed ID: 36061356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-PD-(L)1 for KRAS-mutant advanced non-small-cell lung cancers: a meta-analysis of randomized-controlled trials.
    Landre T; Justeau G; Assié JB; Chouahnia K; Davoine C; Taleb C; Chouaïd C; Duchemann B
    Cancer Immunol Immunother; 2022 Mar; 71(3):719-726. PubMed ID: 34378081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of immune checkpoint inhibitors in the treatment of non-small cell lung cancer patients with different genes mutation: A meta-analysis.
    Zhang R; Zhu J; Liu Y; Xin Y; Wang Y; Niu K; Wei H
    Medicine (Baltimore); 2021 Mar; 100(10):e19713. PubMed ID: 33725808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The efficacy and prognostic factors of immunotherapy in advanced non-small cell lung cancer patients with different driver gene mutations].
    Ma SX; Ma N; Han J; He Z; Wang L; Wang Q
    Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(13):922-929. PubMed ID: 35385963
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of Efficacy and Safety of Single and Double Immune Checkpoint Inhibitor-Based First-Line Treatments for Advanced Driver-Gene Wild-Type Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
    Xu Q; Zhang X; Huang M; Dai X; Gao J; Li S; Sheng L; Huang K; Wang J; Liu L
    Front Immunol; 2021; 12():731546. PubMed ID: 34484242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials.
    Khan M; Lin J; Liao G; Tian Y; Liang Y; Li R; Liu M; Yuan Y
    Medicine (Baltimore); 2018 Aug; 97(33):e11936. PubMed ID: 30113497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR mutation status in non-small cell lung cancer receiving PD-1/PD-L1 inhibitors and its correlation with PD-L1 expression: a meta-analysis.
    Yang H; Zhu J; Xiao R; Liu Y; Yu F; Cai L; Qiu M; He F
    Cancer Immunol Immunother; 2022 May; 71(5):1001-1016. PubMed ID: 34542660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Ba H; Liu L; Peng Q; Chen J; Zhu YD
    BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
    Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C
    J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients with KRAS mutations: A network meta-analysis.
    Zhang L; Chen W; Wei H; Yu J
    Clin Respir J; 2024 Apr; 18(4):e13745. PubMed ID: 38566277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The correlation between programmed death-ligand 1 expression and driver gene mutations in NSCLC.
    Yang H; Chen H; Luo S; Li L; Zhou S; Shen R; Lin H; Xie X
    Oncotarget; 2017 Apr; 8(14):23517-23528. PubMed ID: 28423587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation.
    Zhang B; Zeng J; Zhang H; Zhu S; Wang H; He J; Yang L; Zhou N; Zu L; Xu X; Song Z; Xu S
    Front Immunol; 2022; 13():974581. PubMed ID: 36159860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
    Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 expression and EGFR status in advanced non-small-cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis.
    Li J; Gu J
    Future Oncol; 2019 May; 15(14):1667-1678. PubMed ID: 31041879
    [No Abstract]   [Full Text] [Related]  

  • 15. A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors.
    Kartolo A; Feilotter H; Hopman W; Fung AS; Robinson A
    Cancer Treat Res Commun; 2021; 27():100330. PubMed ID: 33581492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials.
    Li ZQ; Yan HC; Gu JJ; Yang YL; Zhang MK; Fang XJ
    Pharmacol Res; 2020 Oct; 160():105194. PubMed ID: 32937178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prevalence and real-world therapeutic analysis of Chinese patients with KRAS-Mutant Non-Small Cell lung cancer.
    Chen H; Huang D; Lin G; Yang X; Zhuo M; Chi Y; Zhai X; Jia B; Wang J; Wang Y; Li J; An T; Wu M; Wang Z; Zhao J
    Cancer Med; 2022 Oct; 11(19):3581-3592. PubMed ID: 35394121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRAS
    Ricciuti B; Alessi JV; Elkrief A; Wang X; Cortellini A; Li YY; Vaz VR; Gupta H; Pecci F; Barrichello A; Lamberti G; Nguyen T; Lindsay J; Sharma B; Felt K; Rodig SJ; Nishino M; Sholl LM; Barbie DA; Negrao MV; Zhang J; Cherniack AD; Heymach JV; Meyerson M; Ambrogio C; Jänne PA; Arbour KC; Pinato DJ; Skoulidis F; Schoenfeld AJ; Awad MM; Luo J
    Ann Oncol; 2022 Oct; 33(10):1029-1040. PubMed ID: 35872166
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Yang D; Feng Y; Lu H; Chen K; Xu J; Li P; Wang T; Xia D; Wu Y
    J Zhejiang Univ Sci B; 2023 Feb; 24(2):143-156. PubMed ID: 36751700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.